Bank of America Corporation Lowers Sage Therapeutics, Inc. (SAGE) Price Target to $101.00

Sage Therapeutics, Inc. (NASDAQ:SAGE) had its target price cut by Bank of America Corporation from $103.00 to $101.00 in a research note published on Thursday. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on SAGE. Canaccord Genuity cut their price target on shares of Sage Therapeutics from $110.00 to $81.00 and set a buy rating on the stock in a research note on Tuesday, September 12th. SunTrust Banks, Inc. restated a buy rating and set a $82.00 price target (down previously from $95.00) on shares of Sage Therapeutics in a research note on Wednesday, September 13th. Royal Bank Of Canada restated a buy rating and set a $117.00 price target on shares of Sage Therapeutics in a research note on Wednesday, October 18th. Stifel Nicolaus initiated coverage on shares of Sage Therapeutics in a research note on Wednesday, August 9th. They set a buy rating and a $104.00 price target on the stock. Finally, BMO Capital Markets upped their price target on shares of Sage Therapeutics from $80.00 to $84.00 and gave the company an outperform rating in a research note on Thursday, September 14th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $105.71.



Sage Therapeutics (NASDAQ:SAGE) opened at $85.68 on Thursday. Sage Therapeutics has a 52 week low of $44.55 and a 52 week high of $99.80.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The business’s revenue for the quarter was up .0% on a year-over-year basis. research analysts predict that Sage Therapeutics will post -7.38 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/20/bank-of-america-corporation-lowers-sage-therapeutics-inc-sage-price-target-to-101-00.html.

Several hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its holdings in shares of Sage Therapeutics by 1.1% in the 1st quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 62 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sage Therapeutics by 11.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares during the last quarter. Keybank National Association OH boosted its holdings in shares of Sage Therapeutics by 10.6% in the 2nd quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Sage Therapeutics by 19.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 497 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Sage Therapeutics by 0.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock valued at $4,723,000 after acquiring an additional 552 shares during the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply